The Covid-19 pandemic has brought the spotlight on the health-promotive and disease-preventive solutions of Ayush disciplines. What has not come into the limelight is the emerging nation-wide trend in the Ayush disciplines, of taking up evidence-based studies.
Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ® (tofacitinib) for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight. This approval makes XELJANZ the first and only Janus kinase (JAK) inhibitor approved in the U.S. for the treatment of pcJIA.